103 related articles for article (PubMed ID: 7879180)
1. Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury.
Yin M; Kurvers HA; Buurman WA; Tangelder GJ; Booster MH; Daemen JH; Kondracki S; Kootstra G
Transplant Proc; 1995 Feb; 27(1):774-6. PubMed ID: 7879180
[No Abstract] [Full Text] [Related]
2. Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury.
Yin M; Kurvers HA; Buurman WA; Tangelder GJ; Tiebosch AT; Daemen JH; Kootstra G
Transplant Proc; 1995 Oct; 27(5):2844-6. PubMed ID: 7482939
[No Abstract] [Full Text] [Related]
3. Donor administration of PAF antagonist (TCV-309) enhances lung preservation.
Ide S; Kawahara K; Takahashi T; Sasaki N; Shingu H; Nagayasu T; Yamamoto S; Tagawa T; Tomita M
Transplant Proc; 1995 Feb; 27(1):570-3. PubMed ID: 7879103
[No Abstract] [Full Text] [Related]
4. Extended lung preservation with platelet-activating factor-antagonist TCV-309 in combination with prostaglandin E1.
Qayumi AK; English JE; Duncan S; Ansley DM; Pearson B; Nikbakht-Sangari M; Sammartino C; Fradet G
J Heart Lung Transplant; 1997 Sep; 16(9):946-55. PubMed ID: 9322146
[TBL] [Abstract][Full Text] [Related]
5. The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia.
Yin M; Buurman WA; Daemen JW; Kootstra G
Transplantation; 1996 May; 61(10):1443-6. PubMed ID: 8633367
[TBL] [Abstract][Full Text] [Related]
6. The effects of platelet activating factor antagonist, TCV309, on the relationship between electrophysiological and mechanical status during myocardial ischemia and reperfusion.
Tamura K; Kimura Y; Tamura T; Kitashiro S; Izuoka T; Iwasaka T; Inada M
Ann N Y Acad Sci; 1994 Jun; 723():371-4. PubMed ID: 8030887
[No Abstract] [Full Text] [Related]
7. The effect of the platelet-activating factor inhibitor TCV-309 on reperfusion injury in a canine model of ischemic lung.
Kawahara K; Tagawa T; Takahashi T; Akamine S; Nakamura A; Yamamoto S; Muraoka S; Tomita M
Transplantation; 1993 Jun; 55(6):1438-9. PubMed ID: 8516834
[No Abstract] [Full Text] [Related]
8. Platelet activating factor (PAF) antagonists: development of a highly potent PAF antagonist, TCV-309.
Takatani M; Maezaki N; Imura Y; Terashita Z; Nishikawa K; Tsushima S
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():943-6. PubMed ID: 1825438
[No Abstract] [Full Text] [Related]
9. Pharmacological profile of TCV-309--a potent PAF antagonist.
Terashita Z; Takatani M; Nishikawa K
J Lipid Mediat; 1992; 5(2):183-5. PubMed ID: 1445598
[TBL] [Abstract][Full Text] [Related]
10. The roles of platelet-activating factor and endothelin-1 in renal damage after total hepatic ischemia and reperfusion.
Suzuki S; Serizawa A; Sakaguchi T; Tsuchiya Y; Kojima Y; Okamoto K; Kurachi K; Konno H; Fujise Y; Baba S; Nakamura S
Transplantation; 2000 Jun; 69(11):2267-73. PubMed ID: 10868624
[TBL] [Abstract][Full Text] [Related]
11. Platelet activating factor antagonist has a protective effect on preservation/reperfusion injury of the graft in pig liver transplantation.
Takada Y; Boudjema K; Jaeck D; Chenard MP; Wolf P; Cinqualbre J; Yamaoka Y
Transplant Proc; 1995 Feb; 27(1):747-8. PubMed ID: 7879169
[No Abstract] [Full Text] [Related]
12. Role of platelet activating factor in cardiac dysfunction, apoptosis and nitric oxide synthase mRNA expression in the ischemic-reperfused rabbit heart.
Loucks EB; Godin DV; Walley KR; McManus BM; Rahimian R; Granville DJ; Hong JM; Aktary FM; Qayumi AK
Can J Cardiol; 2003 Mar; 19(3):267-74. PubMed ID: 12677282
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of a PAF antagonist against liver injury induced by warm ischemia or cold preservation.
Wang KS; Monden M; Kanai T; Umeshita K; Ukei T; Nakano H; Gotoh M; Mori T
Transplant Proc; 1992 Aug; 24(4):1596-8. PubMed ID: 1496669
[No Abstract] [Full Text] [Related]
14. Platelet-activating factor in hepatic ischemia/reperfusion injury. The effects of a PAF antagonist combined with a prostaglandin I2 analogue.
Nishiyama R; Nakamura S; Suzuki S; Baba S
Transplantation; 1993 Jun; 55(6):1261-5. PubMed ID: 8516812
[TBL] [Abstract][Full Text] [Related]
15. Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees.
Kuipers B; van der Poll T; Levi M; van Deventer SJ; ten Cate H; Imai Y; Hack CE; ten Cate JW
J Immunol; 1994 Mar; 152(5):2438-46. PubMed ID: 8133055
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of lipo-prostaglandin-E1 on warm ischemic kidney injury.
Numajiri Y; Taguchi Y; Koyama I; Sukigara M; Omoto R
Transplant Proc; 1994 Aug; 26(4):2397-401. PubMed ID: 8066787
[No Abstract] [Full Text] [Related]
17. TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock.
Canale P; Squadrito F; Altavilla D; Ioculano M; Zingarelli B; Campo GM; Urna G; Sardella A; Squadrito G; Caputi AP
Agents Actions; 1994 Oct; 42(3-4):128-34. PubMed ID: 7879698
[TBL] [Abstract][Full Text] [Related]
18. Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs.
Kawamura M; Kitayoshi T; Terashita Z; Fujiwara S; Takatani M; Nishikawa K
J Lipid Mediat Cell Signal; 1994 May; 9(3):255-65. PubMed ID: 7921785
[TBL] [Abstract][Full Text] [Related]
19. Role of platelet activating factor in ischaemia-reperfusion injury of isolated rabbit hearts: protective effect of a specific platelet activating factor antagonist, TCV-309.
Katoh S; Toyama J; Kodama I; Koike A; Abe T
Cardiovasc Res; 1993 Aug; 27(8):1430-4. PubMed ID: 8221795
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of platelet-activating factor antagonism in the management of myocardial infarction.
Loucks EB; Qayumi AK; Godin DV; English JC; Lim SP; Al Mahmeed T; Gul S
Can J Cardiol; 2000 Apr; 16(4):497-504. PubMed ID: 10787465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
